Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.

@article{citeulike:2644500, abstract = {PURPOSE: In patients with advanced colorectal cancer, leucovorin, fluorouracil, and irinotecan (FOLFIRI) is considered as one of the reference first-line treatments. However, only about half of treated patients respond to this regimen, and there is no clinically useful marker that predicts response. A major clinical challenge is to identify the subset of patients who could benefit from this chemotherapy. We aimed to identify a gene expression profile in primary colon cancer tissue that could predict chemotherapy response. PATIENTS AND METHODS: Tumor colon samples from 21 patients with advanced colorectal cancer were analyzed for gene expression profiling using Human Genome GeneChip arrays U133. At the end of the first-line treatment, the best observed response, according to WHO criteria, was used to define the responders and nonresponders. Discriminatory genes were first selected by the significance analysis of microarrays algorithm and the area under the receiver operating characteristic curve. A predictor classifier was then constructed using support vector machines. Finally, leave-one-out cross validation was used to estimate the performance and the accuracy of the output class prediction rule. RESULTS: We determined a set of 14 predictor genes of response to FOLFIRI. Nine of nine responders (100\% specificity) and 11 of 12 nonresponders (92\% sensitivity) were classified correctly, for an overall accuracy of 95\%. CONCLUSION: After validation in an independent cohort of patients, our gene signature could be used as a decision tool to assist oncologists in selecting colorectal cancer patients who could benefit from FOLFIRI chemotherapy, both in the adjuvant and the first-line metastatic setting.}, address = {Centre National de la Recherche Scientifique Unit\'{e} Mixte de Recherche 5160, Service d'Anatomie pathologique, Service d'Oncologie Digestive, Montpellier, France. mdelrio@valdorel.fnclcc.fr}, author = {Del Rio, M. and Molina, F. and Bascoul-Mollevi, C. and Copois, V. and Bibeau, F. and Chalbos, P. and Bareil, C. and Kramar, A. and Salvetat, N. and Fraslon, C. and Conseiller, E. and Granci, V. and Leblanc, B. and Pau, B. and Martineau, P. and Ychou, M. }, citeulike-article-id = {2644500}, doi = {10.1200/JCO.2006.07.4187}, issn = {1527-7755}, journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, keywords = {colon\_cancer, gene\_expression, therapy}, month = {March}, number = {7}, pages = {773--780}, posted-at = {2008-04-09 13:19:40}, priority = {0}, title = {Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.}, url = {http://dx.doi.org/10.1200/JCO.2006.07.4187}, volume = {25}, year = {2007} }

TY - JOUR ID - citeulike:2644500 L3 - citeulike-article-id:2644500 TI - Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology VL - 25 IS - 7 SP - 773 EP - 780 AD - Centre National de la Recherche Scientifique Unité Mixte de Recherche 5160, Service d'Anatomie pathologique, Service d'Oncologie Digestive, Montpellier, France. mdelrio@valdorel.fnclcc.fr SN - 1527-7755 N2 - PURPOSE: In patients with advanced colorectal cancer, leucovorin, fluorouracil, and irinotecan (FOLFIRI) is considered as one of the reference first-line treatments. However, only about half of treated patients respond to this regimen, and there is no clinically useful marker that predicts response. A major clinical challenge is to identify the subset of patients who could benefit from this chemotherapy. We aimed to identify a gene expression profile in primary colon cancer tissue that could predict chemotherapy response. PATIENTS AND METHODS: Tumor colon samples from 21 patients with advanced colorectal cancer were analyzed for gene expression profiling using Human Genome GeneChip arrays U133. At the end of the first-line treatment, the best observed response, according to WHO criteria, was used to define the responders and nonresponders. Discriminatory genes were first selected by the significance analysis of microarrays algorithm and the area under the receiver operating characteristic curve. A predictor classifier was then constructed using support vector machines. Finally, leave-one-out cross validation was used to estimate the performance and the accuracy of the output class prediction rule. RESULTS: We determined a set of 14 predictor genes of response to FOLFIRI. Nine of nine responders (100% specificity) and 11 of 12 nonresponders (92% sensitivity) were classified correctly, for an overall accuracy of 95%. CONCLUSION: After validation in an independent cohort of patients, our gene signature could be used as a decision tool to assist oncologists in selecting colorectal cancer patients who could benefit from FOLFIRI chemotherapy, both in the adjuvant and the first-line metastatic setting. KW - colon_cancer KW - gene_expression KW - therapy AU - Del Rio, M AU - Molina, F AU - Bascoul-Mollevi, C AU - Copois, V AU - Bibeau, F AU - Chalbos, P AU - Bareil, C AU - Kramar, A AU - Salvetat, N AU - Fraslon, C AU - Conseiller, E AU - Granci, V AU - Leblanc, B AU - Pau, B AU - Martineau, P AU - Ychou, M PY - 2007/03/01/ UR - http://dx.doi.org/10.1200/JCO.2006.07.4187 ER -